Clinical Improvement and drastic reduction of Equivalent Dose of Levodopa (LEDD) in an Advanced Parkinson’s Disease Patient after Levodopa/Entacapone/Carbidopa Intestinal Gel (LECIG) Treatment
Objective: Describe a patient in which after starting continuous infusion of LECIG a large reduction of the LEDD is achieved. Background: Gastroparesis (GP) is one…Gut microbiota dysbiosis in Parkinson’s disease patients: a potential biomarker of disease severity and progression?
Objective: To investigate gut microbiota alterations in Parkinson's disease (PD) along disease progression. Background: Gut microbiota dysbiosis is considered a hallmark in PD1. However, it is…Efficacy of a four-strain probiotic on gut dysbiosis, motor and non-motor symptoms in Parkinson`s disease: a multicentre randomised controlled trial
Objective: To evaluate the effect of a four-strain probiotic (Lacticaseibacillus rhamnosus, Enterococcus faecium, Lactobacillus acidophilus, Lactiplantibacillus plantarum) on gut microbiota composition, motor and non-motor symptoms…Effect of multi-strain probiotics on gut microbiome and metabolites in Parkinson’s Disease
Objective: We investigated the effects of multi-strain probiotics administration on gut microbiome and metabolites, and markers of intestinal permeability and inflammation. Background: Probiotics have been…Intestinal microbial dysbiosis promotes prebiotic-reversible inflammation in Parkinson’s disease
Objective: To determine the functional effects of disrupted intestinal microbiota in Parkinson’s disease (PD), particularly the impacts of dysbiosis on inflammation, neuroprotective hormone secretion, and…Characterization of gastrointestinal dysfunction in Parkinson’s by disease stage
Objective: To conduct a comprehensive cross-sectional and longitudinal characterization of gastrointestinal dysfunction (GID) in Parkinson’s disease (PD). Background: GID is an important feature of PD…Molecular alterations and pathological remodeling of colonic wall in patients with Parkinson’s disease
Objective: To evaluate, in an integrated manner, changes in faecal microbiota composition, morpho-functional alterations of the colonic mucosal barrier and changes of inflammatory markers in…GASTROINTESTINAL SYMPTOMS ARE ASSOCIATED WITH LEFT PREDOMINANT DOPAMINE TRANSPORTER BINDING DEFICIT IN PARKINSON´S DISEASE
Objective: To assess correlations between functional gastrointestinal (GI) symptoms and nigrostriatal dopamine transporter imaging asymmetry in Parkinson´s disease (PD) patients. Based on a theory that…Functional Constipation in Parkinson’s Disease
Objective: To analyze and compare the Rome IV Criteria of Functional Constipation between PD and HC, with that followed by MDS-NMS, intended for determining clinical…A53T-SNCA-BAC transgenic mouse exhibits multiple prodromal symptoms of Parkinson’s disease: Gastrointestinal dysfunction, hyposmia and RBD-like behavior.
Objective: To develop biomarkers and disease-modifying therapies for Parkinson’s disease, an animal model that recapitulates the early phase of the disease is indispensable. The aim…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 10
- Next Page »